NO163131C - Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater. - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater.

Info

Publication number
NO163131C
NO163131C NO853226A NO853226A NO163131C NO 163131 C NO163131 C NO 163131C NO 853226 A NO853226 A NO 853226A NO 853226 A NO853226 A NO 853226A NO 163131 C NO163131 C NO 163131C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically active
pyridine derivatives
analogous process
active pyridine
Prior art date
Application number
NO853226A
Other languages
English (en)
Norwegian (no)
Other versions
NO853226L (no
NO163131B (no
Inventor
Akira Nohara
Yoshitaka Maki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15916456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO163131(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO853226L publication Critical patent/NO853226L/no
Publication of NO163131B publication Critical patent/NO163131B/no
Publication of NO163131C publication Critical patent/NO163131C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO853226A 1984-08-16 1985-08-15 Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater. NO163131C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59171069A JPS6150978A (ja) 1984-08-16 1984-08-16 ピリジン誘導体およびその製造法

Publications (3)

Publication Number Publication Date
NO853226L NO853226L (no) 1986-02-17
NO163131B NO163131B (no) 1990-01-02
NO163131C true NO163131C (no) 1994-10-24

Family

ID=15916456

Family Applications (2)

Application Number Title Priority Date Filing Date
NO853226A NO163131C (no) 1984-08-16 1985-08-15 Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater.
NO1995002C NO1995002I1 (no) 1984-08-16 1995-03-31 Lansoprazol/ 2-[3-metyl-4-(2,2,2-trifluoretoksy)-pyrid-2-yl]metylsylfinylbenzimidazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1995002C NO1995002I1 (no) 1984-08-16 1995-03-31 Lansoprazol/ 2-[3-metyl-4-(2,2,2-trifluoretoksy)-pyrid-2-yl]metylsylfinylbenzimidazol

Country Status (23)

Country Link
US (2) US4628098A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (1) EP0174726B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (1) JPS6150978A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR920002128B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU570130B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BG (1) BG60415B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA1255314A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DE (3) DE19975017I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (1) DK171340B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (1) ES8607288A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GE (1) GEP19960313B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GR (1) GR851981B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HK (1) HK4792A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (1) HU195210B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IE (1) IE58363B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MX (1) MX9203043A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL930109I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (2) NO163131C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PH (1) PH20946A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (1) SG103291G (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SU (1) SU1507211A3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UA (1) UA7140A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA856117B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174717B1 (en) 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1276017C (en) * 1986-02-13 1990-11-06 Takeda Chemical Industries, Ltd. Sulfenamide derivatives and their production
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
WO1989011479A1 (en) * 1988-05-25 1989-11-30 Byk Gulden Lomberg Chemische Fabrik Gmbh New fluoralkoxy compounds
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
EG19302A (en) * 1988-12-22 1994-11-30 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
EP0382489B1 (en) * 1989-02-10 1994-11-17 Takeda Chemical Industries, Ltd. Use of benzimidazole derivatives as antibacterial agents
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US5312824A (en) * 1990-10-17 1994-05-17 Takeda Chemical Industries, Ltd. Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers
TW209174B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
WO1993006097A1 (en) * 1991-09-20 1993-04-01 Merck & Co., Inc. Novel process for the preparation of anti-ulcer agents
ES2036948B1 (es) * 1991-11-21 1994-09-01 Genesis Para La Investigacion Procedimiento de obtencion de compuestos derivados de piridina.
KR0144793B1 (ko) * 1992-07-08 1998-07-15 제임스 클리프튼 보올딩 돼지에서 위궤양을 완화시키기 위한 벤즈이미다졸
CZ284249B6 (cs) * 1992-07-28 1998-10-14 Astra Aktiebolag Injekce a injekční souprava obsahující omeprazol a jeho analogy
WO1994019346A1 (de) * 1993-02-17 1994-09-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
ES2060541B1 (es) * 1993-02-26 1995-11-16 Vinas Lab Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
ES2063705B1 (es) * 1993-06-14 1995-07-16 S A L V A T Lab Sa Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
ATE198887T1 (de) * 1993-06-29 2001-02-15 Byk Gulden Lomberg Chem Fab Substituierte arylthioalkylthiopyridine
TW280770B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
CN1048980C (zh) * 1994-03-29 2000-02-02 广东汕头鮀滨化学药业总公司 一种新的吡啶衍生物及其制备方法和应用
EP0764160A1 (de) * 1994-06-10 1997-03-26 Byk Gulden Lomberg Chemische Fabrik GmbH Thiopyridine zur bekämpfung von helicobacter-bakterien
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
ATE261303T1 (de) * 1995-09-21 2004-03-15 Pharma Pass Ii Llc Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP2002510293A (ja) * 1997-05-30 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物
ATE281178T1 (de) 1997-07-25 2004-11-15 Altana Pharma Ag Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP2263660B1 (en) 1998-05-18 2017-09-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
IE990506A1 (en) * 1998-06-26 2000-11-15 Russinsky Ltd Pyridine Building Blocks
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
CA2337886C (en) * 1998-07-22 2008-04-08 Sepracor Inc. Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
EP1105387B1 (en) * 1998-08-10 2003-01-29 Winston Pharmateuticals LLC Prodrugs of proton pump inhibitors
WO2000009092A1 (en) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
AU775995B2 (en) 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
DE60020967T2 (de) * 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
KR100359256B1 (ko) * 1999-10-06 2002-11-04 한미약품공업 주식회사 란소프라졸의 개선된 제조방법
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2171116B1 (es) 2000-04-14 2003-08-01 Esteve Quimica Sa Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
EP1293507B1 (en) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
WO2002044167A1 (en) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
KR20030059318A (ko) 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
PT1341524E (pt) 2000-12-07 2011-12-30 Nycomed Gmbh Preparação farmacêutica na forma de uma pasta compreendendo um ingrediente activo lábil a ácido
JP2004514737A (ja) 2000-12-07 2004-05-20 アルタナ　ファルマ　アクチエンゲゼルシャフト 酸分解性活性成分を含有する迅速に崩壊する錠剤
KR100430575B1 (ko) * 2001-02-21 2004-05-10 주식회사 씨트리 란소프라졸 및 그 중간체의 제조방법
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CN1243749C (zh) 2001-09-18 2006-03-01 泽里新药工业株式会社 苯并咪唑衍生物
EP1437352A4 (en) * 2001-09-25 2004-12-08 Takeda Chemical Industries Ltd BENZIMIDAZOLE COMPOUND, METHOD FOR THE PRODUCTION AND USE THEREOF
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DK2258351T3 (da) 2001-10-17 2013-08-26 Takeda Pharmaceutical Granula indeholdende lansoprazol i stor mængde
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
RU2215739C1 (ru) * 2002-04-03 2003-11-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 5-метокси-2-(4-метокси-3,5-диметил-2-пиридилметилтио)бензимидазола
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
JP4698950B2 (ja) 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
KR100822981B1 (ko) * 2002-07-19 2008-04-16 윈스턴 파마슈티컬즈, 엘엘씨 벤즈이미다졸 유도체 및 이들의 프로톤 펌프 억제제의프로드럭으로서의 이용
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004012659A2 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
EP1501824B1 (en) 2002-08-21 2007-10-10 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
BRPI0313611B1 (pt) 2002-08-30 2018-03-06 Astrazeneca Ab Composição farmacêutica para o tratamento de rinite alérgica e/ou conjuntivite alérgica para aplicação na mucosa e uso de dita composição
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
ES2237354T3 (es) * 2002-11-18 2007-11-01 Teva Pharmaceutical Industries Ltd. Lansoprazol estable que contiene mas de 500 ppm, hasta aproximadamente 3.000 ppm de agua y mas de 200 ppm, hasta aproximadamente 5.000 ppm de alcohol.
EP1743893A1 (en) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
NZ540815A (en) 2002-12-06 2008-03-28 Nycomed Gmbh Process for preparing optically pure active compounds
CA2507889C (en) 2002-12-06 2012-02-07 Altana Pharma Ag Process for preparing (s)-pantoprazole
CA2510849A1 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006516574A (ja) * 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール安定化方法
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004080439A1 (ja) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 高濃度に活性成分を球形核に付着させた医薬組成物
EP1601667A2 (en) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
EP1617842A1 (en) * 2003-04-22 2006-01-25 Dr. Reddy's Laboratories Ltd. Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
EP1615913A2 (en) * 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
KR20060041224A (ko) * 2003-07-15 2006-05-11 알러간, 인코포레이티드 양성자 펌프 억제제의 이성질체적으로 순수한 프로드러그를제조하는 방법
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US20070060621A1 (en) * 2004-02-18 2007-03-15 Hughes Patrick M Methods and compositions for the administration of prodrugs of proton pump inhibitors
WO2005082338A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
JP2007526319A (ja) * 2004-03-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 酸不安定性薬物を含んでなる安定な医薬組成物
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AU2005238215A1 (en) * 2004-04-28 2005-11-10 Nycomed Gmbh Dialkoxy-imidazopyridines derivatives
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN101056869B (zh) 2004-09-13 2012-09-26 武田药品工业株式会社 氧化化合物的制备方法和制备装置
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
AU2005306579B2 (en) 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
EP1681056A1 (en) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
ES2550626T5 (es) 2005-02-25 2019-01-15 Takeda Pharmaceuticals Co Método para producir gránulos
KR100771659B1 (ko) 2005-03-23 2007-10-30 주식회사 카이로제닉스 판토프라졸 및 그 중간체의 제조방법
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
JPWO2006132217A1 (ja) * 2005-06-07 2009-01-08 武田薬品工業株式会社 ベンズイミダゾール化合物の塩の結晶
JPWO2006134877A1 (ja) * 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
ZA200805646B (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Controlled release solid preparation
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
ES2374730T3 (es) * 2006-03-10 2012-02-21 Arigen Pharmaceuticals, Inc. Nuevo derivado de piridina que tiene actividad contra helicobacter pylori.
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008035189A1 (en) * 2006-09-22 2008-03-27 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of lansoprazole
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP2124884B1 (en) 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
TW200840574A (en) * 2007-04-02 2008-10-16 Univ Nat Taiwan The pharmaceutical component for treating hearing loss disease
US20100210847A1 (en) * 2007-07-17 2010-08-19 Ranbaxy Laboratories Limited Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
EP2203068A4 (en) 2007-10-12 2012-08-22 Takeda Pharmaceuticals Usa Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES INDEPENDENT FROM FOOD STORAGE
US20100280077A1 (en) * 2007-12-18 2010-11-04 Watson Pharma Private Limited Process for Preparation of Stable Amorphous R-Lansoprazole
WO2009088857A1 (en) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r) -2- [ [ [3-methyl-4- (2, 2, 2-trifluoroethoxy) -2-pyridinyl] methyl] sulfinyl] -1h-benz imidazole
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
AR070972A1 (es) 2008-03-10 2010-05-19 Takeda Pharmaceutical Cristal de compuestos de bencimidazol (lansoprazol)
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
NZ589150A (en) 2008-05-14 2012-03-30 Watson Pharma Private Ltd Stable r (+) -lansoprazole amine salt and a process for preparing the same
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2350044A4 (en) * 2008-10-10 2012-06-06 Celtaxsys Inc PROCESS FOR INTRODUCTION OF NEGATIVE CHEMOTAXIS
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102481293A (zh) 2009-06-25 2012-05-30 阿斯利康(瑞典)有限公司 治疗具有发展nsaid-相关的溃疡的风险的患者的方法
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
UY33173A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) * 2010-01-08 2011-07-29 Eurand Inc
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20130243859A1 (en) 2010-12-03 2013-09-19 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EA028217B1 (ru) 2010-12-27 2017-10-31 Такеда Фармасьютикал Компани Лимитед Разрушающаяся во рту таблетка (варианты)
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
WO2013081177A1 (en) 2011-11-30 2013-06-06 Takeda Pharmaceutical Company Limited Dry coated tablet
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
CN108057028A (zh) 2013-01-15 2018-05-22 铁木医药有限公司 片剂形式的肠溶包衣的胃内滞留口服剂型及其应用和药物组合物
TW201532635A (zh) 2013-05-21 2015-09-01 Takeda Pharmaceutical 口腔內崩解錠
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CN107365300B (zh) * 2017-07-26 2019-08-02 桂林华信制药有限公司 一种有效去除兰索拉唑粗品中杂质的方法
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN114163419A (zh) * 2021-12-24 2022-03-11 辰欣药业股份有限公司 一种兰索拉唑的制备方法
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds

Also Published As

Publication number Publication date
US4689333A (en) 1987-08-25
NO853226L (no) 1986-02-17
HUT39444A (en) 1986-09-29
GR851981B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 1985-12-16
DK356485A (da) 1986-02-17
EP0174726A1 (en) 1986-03-19
IE58363B1 (en) 1993-09-08
NL930109I1 (nl) 1993-10-18
MX9203043A (es) 1992-07-01
AU570130B2 (en) 1988-03-03
AU4589585A (en) 1986-02-20
US4628098A (en) 1986-12-09
DE19975020I2 (de) 2009-08-06
ZA856117B (en) 1986-04-30
CA1255314A (en) 1989-06-06
DE19975017I2 (de) 2009-08-06
SG103291G (en) 1993-02-19
JPH0244473B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 1990-10-04
ES546152A0 (es) 1986-05-16
HU195210B (en) 1988-04-28
DK356485D0 (da) 1985-08-06
BG60415B2 (bg) 1995-02-28
ES8607288A1 (es) 1986-05-16
SU1507211A3 (ru) 1989-09-07
PH20946A (en) 1987-06-10
NL930109I2 (nl) 1997-02-03
JPS6150978A (ja) 1986-03-13
IE851976L (en) 1986-02-16
DE3569736D1 (en) 1989-06-01
KR920002128B1 (ko) 1992-03-12
DK171340B1 (da) 1996-09-16
NO163131B (no) 1990-01-02
UA7140A1 (uk) 1995-06-30
KR870002125A (ko) 1987-03-30
EP0174726B1 (en) 1989-04-26
NO1995002I1 (no) 1995-03-31
GEP19960313B (en) 1996-06-24
HK4792A (en) 1992-01-17

Similar Documents

Publication Publication Date Title
NO163131C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater.
FI883739A7 (fi) Menetelmä terapeuttisesti aktiivisten fenoksi-indaanimetyyliamiinijohdannaisten valmistamiseksi
NO177387C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazo-kondenserte, 6-leddede, heterocykliske forbindelser
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
NO159016C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolaminderivater.
FI875660L (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
FI875024A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1-alkyyli-6-halogeenitetrahydronaftaleenijohdannaisten valmistamiseksi
FI873205A0 (fi) Menetelmä terapeuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO853293L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO173442C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater
FI850654A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pleuromutilinijohdannaisten valmistamiseksi
NO176713C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-aminopyridinderivater
NO176275C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazinonderivater
NO864110L (no) Fremgangsmaate for fremstilling av terapeutisk virksomme benzimidazolderivater.
NO173334C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive alkylaminoalkylenderivater 2H-1-benzopyraner
NO174959C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive N-aminobutyl-N-fenyl-arylamidderivater
FI861903A7 (fi) Menetelmä terapeuttisesti aktiivisten 2-substituoitujen 1-naftolijohdannaisten valmistamiseksi
FI884553A7 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
FI871087A7 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
FI93215C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
FI882002L (fi) Menetelmä terapeuttisesti aktiivisten fenyylipiperidiinijohdannaisten valmistamiseksi
FI880190A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia tetrahydrofuraanijohdoksia
NO163330C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive isokinolinderivater.

Legal Events

Date Code Title Description
MK1K Patent expired